Fennec Pharmaceuticals (TSE:FRX) Share Price Passes Above 50 Day Moving Average – Should You Sell?

Fennec Pharmaceuticals Inc. (TSE:FRX)’s share price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$8.86 and traded as high as C$9.46. Fennec Pharmaceuticals shares last traded at C$9.46, with a volume of 408 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Stephens upgraded shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th.

Fennec Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 1,040.68, a current ratio of 8.02 and a quick ratio of 10.17. The firm has a market capitalization of C$258.83 million, a P/E ratio of 94.60 and a beta of 0.25. The company’s 50 day moving average price is C$8.86 and its 200 day moving average price is C$7.70.

Insider Buying and Selling at Fennec Pharmaceuticals

In other Fennec Pharmaceuticals news, Senior Officer Robert Christopher Andrade purchased 15,816 shares of the stock in a transaction dated Monday, November 18th. The stock was bought at an average price of C$3.43 per share, for a total transaction of C$54,248.88. Also, Director Rostislav Christov Raykov acquired 25,000 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was acquired at an average price of C$3.87 per share, for a total transaction of C$96,840.00. In the last ninety days, insiders have bought 41,612 shares of company stock worth $157,868. Insiders own 16.20% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.